Showing posts with label orthobiologics. Show all posts
Showing posts with label orthobiologics. Show all posts

Wednesday, December 8, 2010

Stryker Moves On From A Long Mistake

One of the traits that often separates the great companies from the average is a willingness on the part of management to quickly identify, isolate and ameliorate mistakes. Instead of allowing doomed products to fester, sucking up cash and eroding morale, dynamic companies pull the plug, take their lumps and move on to better uses of capital.

That makes last night's decision by Stryker (NYSE:SYK) to sell its OP-1 orthopedic product line to Olympus a bit curious in retrospect. While OP-1 was arguably never big enough to be an albatross around the company's neck, it was at the very least a smelly pigeon that was just never going to amount to anything positive. So it is fair to wonder just why the company kept trying to coax growth and success out of a dead-end product.  

Good Riddance To a Bad Product
Stryker announced that it's selling its OP-1 orthobiologics product line (and a manufacturing plant) to Olympus for $60 million in cash. Even with that amount in hand, Stryker will have to recognize between $75 million and $80 million in a non-cash accounting loss to mark down the value on the balance sheet.

Although Stryker has been working on OP-1 for years, it has never really amounted to much. Although the products carry an FDA humane device exemption (HDE) for lumbar spinal fusion and long bone nonunions, the company could never get the FDA to sign off on broad usage. An FDA panel resolutely rejected broad approval of OP-1 putty about 18-months ago with a 6-1 vote. That vote was not very surprising at the time, as the results were pretty ugly and Styker really had to go to some length to find an interpretation of the data that was favorable.
 

Please follow this link for the full piece:
http://stocks.investopedia.com/stock-analysis/2010/Stryker-Moves-On-From-A-Long-Mistake-SYK-MDT-BMTI-BSX1208.aspx

Friday, August 20, 2010

Stocks I'm Looking At - BioMimetic Therapeutics

BioMimetic Therapeutics (Nasdaq: BMTI) is a stock that I have known (and liked) for quite some time and had meant to get around to writing about for this blog for a few weeks. Ultimately, I suppose it took the deal this week between Medtronic (NYSE: MDT) and Osteotech (Nasdaq: OSTE), as well as an email from a reader, to give the poke in the back that I needed.

BioMimetic is an orthobiologics company with a promising new product family (Augment) designed to improve the bone healing process and, perhaps, soft tissue injuries as well.

The key technology in this is the company's synthetic recombinant human platelet-derived growth factor.I know I tend to err sometimes toward "geek speak", so I will try to keep this a little simple (so, for those more technically-inclined, please forgive the simplification!). Basically, this is a synthetic version of a naturally-occurring protein that activates and accelerates the normal musculoskeletal healing process.

Think of it, then, as something like the synthetic human insulins or human growth factor that is administered to diabetics and those with growth disorders - except that in this case, the protein is being delivered not because the patient cannot produce it on his/her own, but rather as a boost to the healing process.

Put simply, apply BMTI's growth factor to a bone fracture or injury and the fracture/injury will heal faster.

Looking across the spectrum of bone healing, spinal fusion, and sports medicine, this could be a $8B+ annual opportunity.  BioMimetic is looking for its first US approval in foot/ankle fusion, but additional applications like long bone repair (the leg or arm, for instance) and spinal fusion are likely to follow. Beyond that, the company is also exploring the use of this technology in soft-tissue repair (cartilage, tendons, etc.).

Phase 3 clinical results in foot/ankle procedures were encouraging. The Augment product demonstrated healing rates that were just as good as autografts (where surgeons harvest bone from elsewhere in the patient's body, like the hip, and use that to fill the void and stimulate healing), but fewer delays in healing, less infection, and substantially less pain. So, it works just as well as the current approach but it has fewer complications and hurts quite a bit less.

So who else is out there in the market? Well, autograft procedures basically require the tools of orthopedic surgery, so that would include Stryker (NYSE: SYK), Biomet (Nasdaq: BMET), Johnson & Johnson (NYSE: JNJ), Zimmer (NYSE: ZMH), Wright Medical (Nasdaq: WMGI) and so on. About 40% or so of most cases end up using autografts.

Outside of autografts, allografts (donor bone) are most common. This is a broad category, and it can mean a host of different graft types, including hard grafts, putties, pastes, and so on. Most orthopedics companies offer these and will often refer to them as "biologics", particularly in those cases where the donor bone has been significantly modified or combined with other ingredients. 

Beyond that are more sophisticated biologic products - products like OP-1 from Stryker and InFuse from Medtronic. These, like Augment, are often delivered as grafts laced with growth factors intended to stimulate healing. InFuse is definitely the leader here, though it can be rather expensive at over $4K per procedure.

Ultimately, I think BioMimetic can win on the combination of solid efficacy, better safety, and less cancer risk (there has been some concern about cancer risks with these growth-stimulating biologics). On top of that, the indicated price range of $2,200 - $2,500 should be very competitive and offering the technology in multiple forms (a spreadable sand-like paste, an injectable paste, et al) will appeal to surgeons.

So what are the risks? Well, the product is not approved yet, and will not go in front of an FDA panel until Q1 of 2011. Although I cannot see why the FDA would turn this down, you never can be 100% sure what the FDA will do. Beyond that, there are the normal risks. Can they compete with Medtronic? Will they get favorable reimbursement? Will surgeons use this off-label and damage their reputation?

None of these bother me all that much, though. I think this stock is extremely cheap (likely worth upwards of $20/sh) and I think risk-tolerant investors who can handle a biotech stock (or a quasi-biotech/med-tech stock) should give this one serious consideration. More likely than not, I think this one gets bought out in the next 12 - 18 months.

I do not have much loose cash right now, but this is a stock that I like enough where I am actually considering selling something to raise the cash. So I may soon be eating my own cooking on this one.


Disclosure - I own shares of JNJ.

Thursday, August 19, 2010

Medtronic Does A Strange Deal

Medtronic (NYSE: MDT) has made some curious moves of late, the most recent of which was the announcement a few days ago that it was buying Osteotech (Nasdaq: OSTE) for $6.50/share in cash ($123 million total).

Like the earlier acquisition of ATS Medical (Nasdaq: ATSI), this is a scratch-and-dent purchase that seems to play to the idea that Medtronic's superior marketing can do more with some interesting-but-not-game-changing technology than these small-caps could.

In the case of Medtronic and Osteotech, Medtronic is buying a small orthobiologics company that has a decent, albeit not exciting, business in demineralized bone matrix products. In simple terms, these are grafts that can be used in procedures like spinal fusion or trauma repair to basically fill a space where bone is supposed to be, with the hope and expectation that bone will then grow into the graft.

In addition to DBM, Osteotech has newer products like MagniFuse, an active biological material taken from allograft but with more human growth factors in it - in other words, allograft bone material with a better likelihood of promoting that bone in-growth. OSTE also has Plexur - a moldable cortical bone and resorbable polymer product.

None of this is going to really shake up business at Medtronic, which already has a sizable orthobiologics business. In addition to InFuse, which is basically a graft laced with recombinant human growth factors that stimulate bone growth, the company is working on getting approval for Amplify. This product (Amplify) is quite similar to InFuse, but carries a higher concentration of the protein ( rhBMP-2) that stimulates bone growth. Unfortunately for Medtronic, though, the clinical results from Amplify have been mixed and a recent FDA panel voted to approve it by the narrowest of margins (6-5).

In any case, Osteotech could be seen as an attempt by Medtronic to back-fill its portfolio and give doctors a more complete suite of biologic options when doing spinal procedures. Plus, I suppose it is at least possible that OSTE has some technology and IP of its own that Medtronic may find useful. After all, if MagniFuse and Plexur were relatively successful new introductions for OSTE, I have to think that Medtronic (and its larger sales support structure) could do even more with it.

For Medtronic investors, this is a yawner. This stock looked cheap before, and it still looks cheap now. I do wonder, though, why the company is now focusing on the small-cap med-tech scrap heap instead of seeking out novel ideas and new technologies.

For Osteotech shareholders, this is the end of a tough road - the $6.50 sales price is the best level this stock has seen in quite a while, and the reality is that Osteotech was going nowhere fast on its own.